immuno oncology frontiers world miami


Jakub Baran

Jakub Baran

CEO & COO, Famicord Group, Polski Bank Komórek Macierzystych S.A.

2005 - COO and then CEO&COO at The Polish Stem Cell Bank (Famicord Group)

Main achievements:

  • organized 4 rounds of financing (Business Angel in 2006, private placement in 2008, private placement in 2009, venture fund in 2009) and sucessfull IPO of the company at Warsaw Stock Exchange in 2016
  • responsible personally for several successful M&A/joint-venture/investment transactions in: Spain, Romania, Poland, Turkey, Hungary, Sweden and more
  • In 2016 Famicord Group became no 1 family stem cell bank in Europe in terms of revenue, profit and numbers of new collections

2002 – co-founder of The Polish Stem Cell Bank (Famicord Group)

2003-2005 – IBM, sales manager telecommunication sector

1995-2003 – Hewlett-Packard, various technical and sales positions

1990-1995 – Technical University of Warsaw, Faculty of Electronics

MSc and Eng. in Digital Signal Processing

Personally fan of strategic games (Baduk, chess), cross-words and SF literaturę.

  • "Great venue to solidify and harmonize on the current challenges facing this sector - in real time. The caliber of the speakers and session contents was premier. “
    Dolores Baksh
    Innovation Leader, GE Healthcare
  • “A great event to learn about the hurdles that are needed to be overcome to get through the clinic.”
    Devin Bridgen
    Scientist, strategic partnerships, SQZ Biotech
  • "It was a great opportunity to share current data and thinking about the development of therapeutics directed at modulating the immune response to cancer."
    Lance Leopold
    Vice President, Head of Oncology Development, Incyte Corporation
  • "Phacilitate provides a unique forum, bringing together research, process development, and commercial leaders on the cutting edge of cell, gene, and immunotherapy. A great conference for anyone wanting a comprehensive view of the field."
    Dr James Trager
    Vice President, Research & Product Development, Dendreon
  • “In the rapidly moving Advanced Therapy market, Phacilitate remains one of the premier events.”
    David James
    CEO, Scinogy